Robert Hoffman

Robert E.
Hoffman currently works at Day For Change, as Director, FibroBiologics, Inc., as Independent Director from 2025, TuHURA Biosciences, Inc., as Director from 2024, Esperion Therapeutics, Inc., as Independent Director from 2025, and CytoDyn, Inc., as Chief Financial & Accounting Officer from 2025.
Mr. Hoffman also formerly worked at Kintara Therapeutics, Inc., as Chairman, President, Chief Executive Officer & CFO from 2023 to 2024, Antibe Therapeutics, Inc., as Chairman from 2022 to 2024, Telik, Inc., as Director, CombiMatrix Corp., as Independent Director from 2013 to 2017, Zeta Acquisition Corp.
III, as Director, Kura Oncology, Inc., as Independent Director from 2015 to 2021, Aslan Pharmaceuticals Ltd., as Independent Non-Executive Director, Versartis, Inc., as Independent Director, Financial Executives International of San Diego Chapter, as President & Director from 2010 to 2020, Saniona AB, as Independent Director from 2021 to 2022, MabVax Therapeutics Holdings, Inc., as Independent Director from 2014 to 2017, Aravive, Inc., as Independent Director from 2018 to 2020, ASLAN Pharmaceuticals Pte Ltd., as Independent Director, Heron Therapeutics, Inc., as Chief Financial Officer & Senior VP-Finance from 2017 to 2020, Document Sciences Corp., as Assistant Controller from 1994 to 1997, Arena Pharmaceuticals, Inc., as Chief Financial Officer & Senior VP-Finance from 2012 to 2015, AnaptysBio, Inc., as Chief Financial Officer from 2015 to 2016, Innovus Pharmaceuticals, Inc., as Chief Financial & Accounting Officer, Executive VP from 2016 to 2017, Polaris Group, Inc., as Chief Financial Officer in 2011, and Arena Pharmaceuticals, Inc., as Chief Financial Officer & Senior VP-Finance.
Mr. Hoffman received his undergraduate degree in 1988 from St. Bonaventure University.